KY-05009

CAT: 0804-HY-124745-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-124745-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity[1].
CAS Number
[1228280-29-2]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; MAP4K; Wnt
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ky-05009.html
Purity
99.88
Solubility
DMSO : 83.33 mg/mL (ultrasonic)
Smiles
O=C(C1=C(NC(C2=CC=C(C)C=C2)=O)SC(NC3=CC=CC=C3)=N1)N
Molecular Formula
C18H16N4O2S
Molecular Weight
352.41
Precautions
H302, H315, H319, H335
References & Citations
[1]Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8 (25) :41091-41101.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MAP4K7/TNIK

Popular Products